In October 2020, we entered into a license agreement with Nevakar for an exclusive license to develop, manufacture, register, import and commercialize NVK-002 in Greater China, South Korea and certain countries in Southeast Asia.

In July 2012, Lee’s Pharm (HK) entered into a license agreement, or the Thymosin 4 License Agreement, with RegeneRx for the license of Thymosin 4 in RGN-259 and any other Thymosin 4-based drug candidates developed by RegeneRx, together, the Thymosin 4-bas

On December 15, 2020, we entered into an exclusive license agreement with PanOptica, Inc. for PAN-90806 (the “PAN-90806 License Agreement”). Under the PAN-90806 License Agreement, PanOptica granted us an exclusive, royalty-bearing, sublicensable license,

In July 2020, we entered into a license agreement with IACTA for the license of certain patents and know-how relating to IC-265 and IC-270 in Greater China and certain Southeast Asia countries.

In September 2016, Zhaoke Pharmaceutical (HK) Limited entered into a license agreement, or the Resolv ER License Agreement, with Kato Pharmaceuticals for an exclusive license of a group of patent rights, or the Kato Patent Rights, and Kato Pharmaceuticals

In January 2017 and April 2020, we entered into a series of product licensing, development and commercialization agreements with TOT BIOPHARM, under which TOT BIOPHARM granted us an exclusive license to commercialize TAB014 for neovascularization-related

In December 2020, we entered into a license and supply agreement with NTC, and we were granted an exclusive license to develop, import, register, obtain price and seek reimbursement, promote, market, distribute and sell NTC014 in Greater China, South Kore